Chronic use, as defined by >  weeks of a corticosteroid agent that is >=  mg/day of prednisone or its equivalent, within  weeks prior to first administration of BI
Recent corticosteroid therapy at a cumulative dose equivalent to >=  mg of prednisone or a single dose equivalent to >=  mg of dexamethasone within  weeks prior the first dose of study drug.
Need of more than  mg/day of prednisone or an equivalent dose of other anti-inflammatory corticosteroids as a current systemic corticosteroid therapy to treat a chronic disease (e.g., rheumatic disorder)
Off or low dose (=<  mg/day by Decadron) corticosteroid for at least for  weeks before the first pre-surgical vaccine
Corticosteroid doses >  mg/day of prednisone or equivalent within  days prior to cycle  day 
Patients who are receiving additional immunosuppressive therapy or any steroids (except concurrent corticosteroid usage if no more than  mg per day, prednisolone equivalent is applied)
Patients may not be receiving systemic corticosteroid therapy at a prednisone dose >  mg/day (or steroid equivalent) within  weeks of starting study.
Corticosteroid therapy at the time the patient enters the protocol; NOTE: patients using prednisone or its equivalent for adrenal failure or using =< mg of prednisone/day for other benign causes are accepted
Need for current chronic corticosteroid therapy (>=  mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids)
Patients requiring corticosteroid therapy at a dose of  mg or more per day of prednisone or the equivalent; pulsed corticosteroid dose for disease control is acceptable
Patients must require no corticosteroid therapy or dose of less than  mg per day of prednisone or the equivalent; pulsed corticosteroid dose for disease control is acceptable until the day before the start of lymphodepletion
The patient must not be on a corticosteroid dose greater than physiologic replacement dosing defined as  mg of cortisone per day or its equivalent
Corticosteroid use =<  weeks prior to registration; NOTE: patients must be off corticosteroids for at least  weeks prior to registration; this includes oral, IV, subcutaneous, or inhaled route of administration; patients on chronic corticosteroid for adrenal insufficiency or other reasons may enroll if they receive less than  mg/day of prednisone (or equivalent)
Corticosteroid use > mg/day of prednisone or equivalent, for purposes other than lymphoma symptom control
Corticosteroid therapy (> mg prednisone/day or equivalent) within  week prior to the first dose of study drug
Patients requiring ongoing daily corticosteroid therapy at a dose of >  mg of prednisone per day (or equivalent); pulsed corticosteroid use for disease control is acceptable
EXCLUSION CRITERIA FOR PATIENTS WITH NSCLC OR TNBC (COHORT B): Patients requiring ongoing daily corticosteroid therapy at a dose of >  mg of prednisone per day (or equivalent); pulsed corticosteroid use for disease control is acceptable
EXCLUSION CRITERIA FOR TNBC: Patients requiring ongoing daily corticosteroid therapy at a dose of >  mg of prednisone per day (or equivalent); pulsed corticosteroid use for disease control is acceptable
Corticosteroid use >  mg/day at time of consent
Immunosuppressive corticosteroid doses (>mg prednisone) within  days prior to treatment with REGN
Patient is on chronic systemic steroid therapy (>  mg/kg prednisone or equivalent) within two weeks before the planned date for first dose randomized treatment or on any other form of immunosuppressive medication (premedication with corticosteroid for nausea is permitted)
Patients requiring ongoing daily corticosteroid therapy at a dose of >  mg of prednisone per day (or equivalent); pulsed corticosteroid use for disease control is acceptable
Chronic systemic corticosteroid use (ie, prednisone >  mg QD or the equivalent of longer duration than  weeks for any medical condition) or history of chronic corticosteroid use (longer than  weeks duration) within the past  months; treatment for well-controlled and asymptomatic adrenal insufficiency is permitted, but replacement dosing is limited to prednisone ?  mg QD or the equivalent, and patients must have no history of adrenal crisis. Local steroid therapies (eg, otic, ophthalmic, intra-articular or inhaled medications) are acceptable
Chronic use (> weeks) of greater than physiologic doses of corticosteroid agent (dose equivalent to ?mg of prednisone) within  days of st day of study drug treatment & during treatment
Short course systemic corticosteroids for disease control, improvement of performance status or non-cancer indication within  days prior to day  of protocol therapy; stable ongoing corticosteroid use (i.e. at least  days) up to an equivalent dose of  mg of prednisone is permissible
Patients with a condition requiring corticosteroid therapy (> mg prednisone/day or equivalent) within  days of randomization
Have received a cumulative dose of corticosteroid ?  mg prednisone (or equivalent doses of corticosteroids) within two weeks before the first Investigational Medicinal Product (IMP) administration.
Systemic anti-myeloma therapy including systemic corticosteroid steroid therapy of greater than  mg/day of prednisone or equivalent dose of another corticosteroid are not allowed within  weeks prior to the required leukapheresis
Patients should not take corticosteroids including prednisone, dexamethasone or any other corticosteroid for any purpose at doses higher than  mg/day of prednisone or equivalent dose of another corticosteroid  weeks before apheresis and within  weeks prior to CAR T-cell infusion, and at any time after the CAR T cell infusion
Systemic corticosteroid steroid therapy of greater than  mg/day of prednisone or equivalent dose of another corticosteroid are not allowed within  weeks prior to either the required leukapheresis or the initiation of the conditioning chemotherapy regimen
Patients receiving a stable dose (>  weeks) of corticosteroid therapy equivalent to  mg of prednisone per day or less are eligible
Current need for chronic corticosteroid therapy or other immunosuppressive agents (>=  mg of prednisone daily or an equivalent dose of other corticosteroid), or patients who have received systemic corticosteroids =<  weeks prior to starting study drug
Need for current chronic corticosteroid therapy (>= mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids)
Chronic use of systemic corticosteroid above an accepted physiologic dose (mg per day of prednisone or equivalent) within  days of enrollment except when used as premedication
No corticosteroid use will be permitted within two weeks prior to study, except for maintenance therapy for a non-malignant disease; maintenance therapy dose may not exceed  mg/day prednisone or equivalent
The patient must not be on a corticosteroid dose greater than physiologic replacement dosing defined as  mg of cortisone per day or its equivalent
Participants with ongoing corticosteroid use > mg per day of prednisone or equivalent
Have received a cumulative dose of corticosteroid ?  mg (prednisone or equivalent doses of corticosteroids) within two weeks before the first infusion.
Chronic systemic corticosteroid use (ie, prednisone >  mg QD or the equivalent); treatment for well-controlled and asymptomatic adrenal insufficiency is permitted, but replacement dosing is limited to prednisone ?  mg QD or the equivalent, and patients must have no history of adrenal crisis. Local steroid therapies (eg, otic, ophthalmic, intra-articular or inhaled medications) are acceptable
Other ongoing or prior anti-myeloma therapy; patients may be receiving concomitant therapy with bisphosphonates and low dose corticosteroids (e.g., prednisone up to but no more than  mg p.o. q.d. or its equivalent) for symptom management and comorbid conditions; doses of corticosteroid should be stable for at least  days prior to study treatment)
Other ongoing anti-myeloma therapy; patients may be receiving concomitant therapy with bisphosphonates and low dose corticosteroids (e.g., prednisone up to but no more than  mg p.o. q.d. or its equivalent) for symptom management and comorbid conditions; doses of corticosteroid should be stable for at least  days prior to study treatment)
Current need for chronic corticosteroid therapy (>=  mg of prednisone daily or an equivalent dose of other corticosteroid), or patients who have received systemic corticosteroids =<  weeks prior to starting study drug
Chronic systemic corticosteroid use at supraphysiologic doses (>=  mg prednisone per day or equivalent)
Short course systemic corticosteroids for disease control, improvement of performance status or non-cancer indication (<  days) must have been discontinued at least  days prior to study treatment; stable ongoing corticosteroid use (>=  days) up to an equivalent dose of  mg of prednisone is permissible
Corticosteroid doses >  mg/day of prednisone or equivalent within  days prior to cycle  day 
Ongoing corticosteroid use > milligrams per day (mg/day) prednisone or equivalent
Corticosteroid administration > mg/day of prednisone or equivalent within  days
Concurrent and chronic therapy with corticosteroids (greater than mg per day of prednisone or an equipotent dose of another corticosteroid) or any other immunosuppressive drugs
Patients must be off corticosteroids for at least  weeks prior to registration; this includes oral, intravenous (IV), subcutaneous, or inhaled route of administration; patients on chronic corticosteroid for adrenal insufficiency or other reasons may enroll if they receive less than  mg/day of prednisone (or equivalent)
Need for current chronic corticosteroid therapy (>=  mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids)
Have received a cumulative dose of corticosteroid ?  mg (prednisone or equivalent doses of corticosteroids) within two weeks before the first infusion.
Ongoing corticosteroid use > milligrams per day (mg/day) of prednisone or equivalent. Participants receiving corticosteroid treatment with less than equal to (</=)  mg/day of prednisone or equivalent must be documented to be on a stable dose of at least  weeks duration prior to randomization (Cycle  Day )
Ongoing corticosteroid use > mg per day prednisone or equivalent, for purposes other than lymphoma symptom control
Need for chronic corticosteroid therapy of >= mg of prednisone per day or an equivalent dose of other anti-inflammatory corticosteroids or immunosuppressants for a chronic disease
Corticosteroid use >  mg prednisone/day
Patients on established, chronic corticosteroid therapy (>  mg /day of prednisone or prednisone equivalent) prior to transplant; established, chronic corticosteroid therapy is defined as daily dosing of >  mg/day of prednisone or prednisone equivalent for at least  weeks prior to the start of conditioning/chemotherapy or plans to continue pre-transplant corticosteroids (>  mg/day of prednisone or prednisone equivalent) indefinitely after transplantation
Requires immunosuppressive doses of corticosteroid therapy (>  mg/day prednisone equivalents) for >=  weeks prior to registration
